Momelotinib Improves Symptoms of Myelofibrosis
The proportion of patients with a 50% or greater reduction in total symptom score was higher with momelotinib than with danazol.
Diagnosis & Disease Information
Momelotinib Bests Danazol in Symptomatic, Anemic Myelofibrosis
Momelotinib proved superior to danazol in patients with symptomatic, anemic myelofibrosis in a phase 3 study.
SARS-CoV-2 Vaccination Reduces Risk of Mortality and Hospitalization in MPNs
A single-center study sought to determine the effects of SARS-CoV-2 vaccination in patients with myeloproliferative neoplasms.
Vonjo Approved for Myelofibrosis With Severe Thrombocytopenia
The approval was based on data from the phase 3 PERSIST-2 trial.
Parsaclisib Improved Myelofibrosis Symptoms in Patients With Suboptimal Response to Ruxolitinib
At 12 weeks, most patients had a reduction in spleen volume.
Imetelstat Shows Clinical Efficacy in Relapsed or Refractory Myelofibrosis
Researchers found that a 9.4 mg/kg dose of imetelstat is more efficacious than a 4.7 mg/kg dose.
Study Results Find Interaction Between Fedratinib and a Strong Inhibitor of CYP3A4
Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.
Imetelstat Active in Myelofibrosis, But May Cause Myelosuppression
Imetelstat was active in patients with myelofibrosis, but had the potential to cause clinically significant myelosuppression.
Prior Myeloproliferative Neoplasm Associated with Poor Outlook for New Primary Cancers
Preceding myeloproliferative neoplasm is a predictor for poor outlook in patients who develop new primary cancers.
In Myelofibrosis, Ruxolitinib Response Associated with Mutation Profile
In patients with myelofibrosis treated with ruxolitinib, harboring three or more mutations was inversely associated with response.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...